ArticleCancer medicine2020
Clinicopathological characteristics and survival of spinal cord astrocytomas.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.Journal of neuro-oncology · 2024Pooled it
- Intraoperative shear wave elastography during surgical treatment of intramedullary spinal cord tumors.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Visualizing spinal tumors: a review of intraoperative contrast enhanced ultrasound during spinal tumor resections.Frontiers in oncology · 2026Review
- H3F3B p.K27I-mutant diffuse midline glioma is a distinct subtype of H3K27-altered diffuse midline glioma.Acta neuropathologica communications · 2025Article
- Independent Prognostic Factors and Nomogram Prediction of Cancer-Specific Survival in Postoperative Patients With Spinal Cord Astrocytoma.Global spine journal · 2025Article
- Sequencing of cerebrospinal fluid cell-free DNA facilitated early differential diagnosis of intramedullary spinal cord tumors.NPJ precision oncology · 2024Article
- Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.Brain pathology (Zurich, Switzerland) · 2023Article
- Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma.Spinal cord · 2022Article
- Article
- Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics.Frontiers in oncology · 2022Review
- Analyses of DNA Methylation Profiling in the Diagnosis of Intramedullary Astrocytomas.Journal of neuropathology and experimental neurology · 2021Article
- Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas.Acta neuropathologica communications · 2021Article
- Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.Frontiers in medicine · 2021Article
- Clinicopathological characteristics and survival of spinal cord astrocytomas.Cancer medicine · 2020Article
- Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to their rarity, the clinicopathological characteristics and prognostic factors of spinal cord gliomas are still unclear. Here, we aimed to clarify these issues in a cohort of 108 spinal cord astrocytomas.
methodsWe characterized the clinicopathological characteristics, including 2016 World Health Organization (WHO) grade, age, sex, location, segment length, resection, pre- and postsurgery, Modified McCormick Scale (MMS), radio- and chemotherapy, and Ki-67 and H3 K27M mutations, in 108 spinal cord astrocytomas through heatmaps. The Cox regression analysis and Kaplan-Meier curves were used to study the prognostic value of these clinicopathological features.
resultsThere are a total 38 H3 K27M-mutant tumors, including 31 cases with histological grade II/III tumors. The age of low-grade astrocytoma patients (WHO grade I/II, n = 54) was significantly younger (27.0 vs 35.5 years, P = .001) than those with high-grade tumors (WHO grade III/IV, n = 54). All patients underwent surgical resection with neurophysiological monitoring, and the surgery did not result in significant changes in MMS. The presurgery MMS was associated with overall survival in the high-grade subgroup (P = .008) but not in the low-grade subgroup (P = .312). While, the high content of resection improved the survival of only patients with low-grade astrocytomas (P = .016) but not those with high-grade astrocytomas (P = .475). Both the low-grade and high-grade astrocytomas had no obvious benefit from neither adjuvant chemotherapy nor radiotherapy (all P > .05).
conclusionsWe characterized the clinicopathological characteristics and their prognostic values in 108 spinal cord astrocytomas, which could help with evidence-based management of spinal cord astrocytomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.